Neonatal Fc receptor FcRn
Neonatal Fc receptor FcRn
2024-09-03
The neonatal Fc receptor (FcRn) binds to the Fc portion of IgG in a pH-dependent manner, protecting it from intracellular degradation. FcRn not only protects IgG but also participa...
B-cell activating factor BAFF
B-cell activating factor BAFF
2024-09-02
BAFF is a B cell-activating factor and a member of the tumor necrosis factor ligand superfamily, member 13B (TNFSF13B, CD57), also known as BLyS. It is a ligand for three receptors...
Human epidermal growth factor receptor HER2
Human epidermal growth factor receptor HER2
2024-08-30
HER2, also known as human epidermal growth factor receptor 2 (ERBB2), plays a crucial role in cell proliferation, survival, and differentiation. HER2 is a key target for the treatm...
Receptor tyrosine kinase-like orphan receptor ROR1
Receptor tyrosine kinase-like orphan receptor ROR1
2024-08-29
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is lowly expressed or absent in normal tissues, but its expression is significantly elevated in a variety of malignancies and...
The target of Fibroblast growth factor receptor FGFR1
The target of Fibroblast growth factor receptor FGFR1
2024-08-28
Fibroblast growth factor receptor 1 ( FGFR1) , a member of the FGFR family , is a transmembrane protein and a receptor tyrosine kinase. It plays a central role in key biological pr...
The IL-7 fusion protein F8 (scDb) IL7 up regulates TCF1 and promotes PD-1 blockade
The IL-7 fusion protein F8 (scDb) IL7 up regulates TCF1 and promotes PD-1 blockade
2024-08-27
BackgroundAnti-PD-1 antibodies have transformed cancer immunotherapy by inducing long-term complete remissions in a subset of patients. However, studies have shown that a significa...
A two-component T-cell activation therapy MATCH
A two-component T-cell activation therapy MATCH
2024-08-26
BackgroundMultispecific T cell adhesion scaffolds have become effective anticancer therapies for hematologic malignancies. Strategies are needed to modulate cancer cell targeting a...